Jollibee Plans U.S. Listing for International Business, Shares Rally 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
MENLO PARK, Calif., April 05, 2016 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York at 8:40 a.m. Eastern Time on Tuesday, April 12, 2016.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/needham76/gern. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
